


## PHARMACEUTICAL 2019

**ESPERION** 

## Esperion Therapeutics Inc. Rank 323 of 371





## PHARMACEUTICAL 2019

**ESPERION** 

## Esperion Therapeutics Inc. Rank 323 of 371

The relative strengths and weaknesses of Esperion Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Esperion Therapeutics Inc. compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 66% points. The greatest weakness of Esperion Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 427% points.

The company's Economic Capital Ratio, given in the ranking table, is -704%, being 373% points below the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	142,632
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	64,333
Liabilities, Non-Current	0
Other Assets	299
Other Compr. Net Income	526
Other Expenses	0
Other Liabilities	0
Other Net Income	2,775
Property and Equipment	520
Research and Development	171,488
Revenues	0
Selling, General and Administrative Expense	33,097

Output Variable	Value in 1000 USD
Assets	143,451
Liabilities	64,333
Expenses	204,585
Stockholders Equity	79,118
Net Income	-201,810
Comprehensive Net Income	-201,547
Economic Capital Ratio	-704%